Terrance Connolly

Over the last year, Dr. Connolly served as Chief Business Officer of Skyhawk Therapeutics, managing all business and development activities at the company. Previously, he held a wide variety of business and operations roles at Celgene Corporation, most recently as the Executive Director of Business Development, where he negotiated multiple transactions to support Celgene's distributed research model.

Dr. Connolly also held executive roles in Celgene's Global Alliances organization, Technical Operations, and Process Chemistry, where he contributed to the successful commercialization of Celgene's Otezla. Prior to working with Celgene, Dr. Connolly held roles in chemical development at Wyeth, Roche and Raylo Chemicals (now Gilead Edmonton). He received his B.Sc. (Honors in Chemistry) from Mount Allison University and a Ph.D. in Organic Chemistry from the University of Ottawa.